Search the Newsreel

Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss

Jasper Therapeutics (JSPR) announced a net loss of $2.8 million for the second quarter ended June 30, 2026. The company recently acquired Kira Pharmaceuticals, raising approximately $132 million, and anticipates releasing interim data and making regulatory filings for its expanded pipeline assets in late …

Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline

(RTTNews) - Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company focused on immune-mediated diseases, reported second quarter 2026 financial results and provided a corporate update following the completion of its acquisition of Kira Pharmaceuticals. The combined company is advancing a portfolio of clinical-stage therapies …

Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary

Jasper Therapeutics, Inc. reported a significant reduction in its net loss for the second quarter of 2026, posting $(2.8M) compared to $(26.7M) in the prior year, with diluted EPS improving to $(0.10) from $(1.74). The company, which remains pre-revenue, highlighted strategic repositioning through the …

Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M

Jasper Therapeutics (JSPR) significantly reduced its net loss in the first half of 2026 to $3.9 million from $48.0 million the previous year, primarily due to lower operating expenses and non-cash adjustments. Subsequent to the quarter, the company acquired Kira Pharmaceuticals, adding new complement-pathway …

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics announced its second quarter 2026 financial results, highlighted by the acquisition of Kira Pharmaceuticals and a successful $132 million PIPE financing. The combined company now possesses a strengthened portfolio of clinical-stage assets for immune-mediated diseases, including KP-104, briquilimab, and KP-701, with sufficient …

JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc

Piper Sandler Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $2

Piper Sandler has initiated coverage of Jasper Therapeutics (JSPR.US) with a Buy rating. The firm has set a price target of $2 for the company's shares.

Jasper Therapeutics Inc (JSPR) Stock News Today

This article from TradingKey provides a brief update on Jasper Therapeutics Inc (JSPR) stock. It notes the current stock price and highlights that more news will be coming soon regarding earnings, analyst ratings, and key developments. The page serves as a placeholder for future …

Jasper Therapeutics (NASDAQ:JSPR): Why Is the Stock Back in Focus as the Latest Update Arrives?

Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therap

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Jasper Therapeutics, Inc. (NASDAQ:JSPR) securities. The investigation focuses on whether Jasper and its officers engaged in corporate wrongdoing, particularly for investors who purchased shares before November 30, 2023, and continue …

Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Jasper Therapeutics, Inc. announced that it has received $131.999613 million in funding from a group of investors

Jasper Therapeutics, Inc. announced that it has successfully raised $131.999613 million in funding from a group of 40 investors. The company closed this transaction on August 5, 2026, by issuing 4,656,071 non-voting convertible preferred shares at an issue price of $28.35 per preferred share. …

Jasper Therapeutics (JSPR) completes $131.9M Rule 506(b) private equity sale

Jasper Therapeutics (JSPR) has successfully completed a private exempt equity offering under Rule 506(b) of Regulation D, raising $131,999,611. The offering was fully subscribed with the first sale occurring on July 21, 2026, and no finders' fees were reported. The biotechnology company, incorporated in …

Jasper Therapeutics, Inc. (JSPR) awards 7,500 stock options to director

Jasper Therapeutics, Inc. (JSPR) director Patrick J. Crutcher was granted 7,500 stock options for Voting Common Stock on July 31, 2026. These options, exercisable at $0.63 per share, will vest in full one year from the grant date, subject to his continued service, and …

Jasper Therapeutics (JSPR) grants director option for 7,500 shares

Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 director, auditor and pay votes

Jasper Therapeutics, Inc. (NASDAQ: JSPR) held its 2026 Annual Meeting of Stockholders on July 31, 2026, where shareholders voted on the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and an advisory vote on …

Jasper Therapeutics (JSPR) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for Jasper Therapeutics (JSPR). It includes information about the stock's performance, projected price targets, and a summary of recent analyst actions.

Jasper Therapeutics Company Profile & Introduction

This article provides a company profile and introduction for Jasper Therapeutics. It likely covers key information about the company's operations, mission, and relevant details, serving as a foundational overview for potential investors or interested parties.

Jasper Therapeutics (Nasdaq: JSPR) outlines $30M CVR tied to briquilimab

Jasper Therapeutics (Nasdaq: JSPR) has detailed the terms of its $30 million contingent value right (CVR) associated with its acquisition of Kira Pharmaceuticals. Holders of Jasper's voting common stock immediately prior to the merger are entitled to one contractual CVR per share. This CVR …

Jasper Therapeutics Inc (JSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Jasper Therapeutics Inc (JSPR), detailing its support, resistance, indicators, and moving averages. It includes a breakdown of various technical indicators like MACD, RSI, and KDJ, alongside moving average signals. The analysis aims to offer investors reference points …

Jasper Therapeutics, Inc. Revenue Breakdown – BOATS:JSPRW

This article provides details for Jasper Therapeutics, Inc. (JSPRW) on the TradingView platform. It highlights that the stock symbol refers to the Blue Ocean Alternative Trade System (BOATS). The content primarily points to different financial data, documents, news, and community features available for JSPRW …

Jasper Therapeutics (JSPR) Slips to $0.62 as Stock Tests Key Support - Profit Surge Picks

Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis

This article from TradingKey provides an analysis of Jasper Therapeutics Inc's (JSPR) financial health, focusing on its profitability and balance sheet. It notes the current stock price and market capitalization. The article is part of TradingKey's financial analysis content.

Jasper Therapeutics Inc (JSPR) Earnings Date & Reports & Earnings News

Jasper Therapeutics Inc (JSPR) Income Statement

This article provides the quarterly and annual income statements for Jasper Therapeutics Inc (JSPR), detailing various financial metrics such as operating expenses, R&D expenses, operating profit, and net income from FY2020Q3 to FY2026Q1. It also includes comprehensive FAQs on how to interpret the income …

Jasper Therapeutics Inc (JSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for Jasper Therapeutics Inc (JSPR), focusing on volatility, financial risk, and investment risk. It presents various financial metrics including Beta, VaR, Maximum Drawdown, Volatility, Sharpe Ratio, and Liquidity indicators over different timeframes. The data shows significant volatility …

Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis

This article from TradingKey provides a valuation overview for Jasper Therapeutics Inc (JSPR), stating that relevant data for P/E, P/B, and P/CF ratios have not yet been disclosed by the company. It notes a recent stock price of $0.688, down 5.58%, with a market …

Jasper Therapeutics Inc (JSPR) Cash Flow Statement

This article provides detailed quarterly and annual cash flow statements for Jasper Therapeutics Inc (JSPR), covering operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flows and their significance for investors. The company's stock symbol is JSPR, …

Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPR

This article provides a basic overview of Jasper Therapeutics, Inc. (NASDAQ: JSPR) focusing on its financial data and market information available on TradingView. It indicates that the primary content, likely detailed revenue breakdown and other financials, would be accessible through the platform's various tools …

JSPR|Jasper Therapeutics Inc|Price:0.689|Chg%:-0.041

Jasper Therapeutics Inc (JSPR) closed at $0.688 with a 5.58% decrease on July 24, 2026. The company, a clinical-stage biotechnology firm, focuses on developing therapeutics for mast cell-driven diseases and severe combined immunodeficiency, with briquilimab as its lead product candidate. Analysts currently rate JSPR …

Enterprise value to EBITDA forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW

This article focuses on the enterprise value to EBITDA forward for Jasper Therapeutics, Inc. (NASDAQ:JSPRW). It appears to be a financial data snippet from TradingView, indicating specific data points for certain periods. The content itself provides the title and mentions "Period," "Value," "Change," and …

Jasper Therapeutics (JSPR) CMO lists merger-based stock option awards

Jasper Therapeutics' Chief Medical Officer, Greg Keenan, has reported initial equity holdings following the merger with Kira Pharmaceuticals. The holdings include stock options for Voting Common Stock and Non-Voting Convertible Preferred Stock, received in exchange for Kira options. These options start vesting in monthly …

Jasper Therapeutics COO Matthew E. Ros files initial beneficial ownership statement

Jasper Therapeutics COO Matthew E. Ros has filed an initial beneficial ownership statement, reporting stock options for 103,204 voting common shares at a price of USD 0.01. This information was generated using AI based on data from the U.S. Securities and Exchange Commission's EDGAR …